A Distribution-based Method for Assessing The Differences between Clinical Trial Target Populations and Patient Populations in Electronic Health Records

C. Weng1,*; Y. Li2,*; P. Ryan3; Y. Zhang5; F. Liu1; J. Gao6; J.T. Bigger7; G. Hripcsak1
1Department of Biomedical Informatics, Columbia University, New York, NY 10032; 2Department of Computer Science, City College of New York, New York, NY 10031; 3Janssen Research and Development, Titusville, New Jersey, 08560; 4Observational Health Data Sciences and Informatics, New York, NY, 10032; 5Department of Biostatistics, Columbia University, New York, NY 10032; 6Business School, Columbia University, New York, NY 10025; 7Department of Medicine, Columbia University, New York, NY 10032; *equal-contribution first authors

Keywords
Clinical trials, selection bias, comparative effectiveness research, electronic health records, clinical research informatics, meta-analysis

Summary
Objective: To improve the transparency of clinical trial generalizability and to illustrate the method using Type 2 diabetes as an example.
Methods: Our data included 1,761 diabetes clinical trials and the electronic health records (EHR) of 26,120 patients with Type 2 diabetes who visited Columbia University Medical Center of New-York Presbyterian Hospital. The two populations were compared using the Generalizability Index for Study Traits (GIST) on the earliest diagnosis age and the mean hemoglobin A1c (HbA1c) values.
Results: Greater than 70% of Type 2 diabetes studies allow patients with HbA1c measures between 7 and 10.5, but less than 40% of studies allow HbA1c<7 and fewer than 45% of studies allow HbA1c>10.5. In the real-world population, only 38% of patients had HbA1c measures between 7 and 10.5, with 12% having values above the range and 52% having HbA1c<7. The GIST for HbA1c was 0.51. Most studies adopted broad age value ranges, with the most common restrictions excluding patients >80 or <18 years. Most of the real-world population fell within this range, but 2% of patients were <18 at time of first diagnosis and 8% were >80. The GIST for age was 0.75.
Conclusions: We contribute a scalable method to profile and compare aggregated clinical trial target populations with EHR patient populations. We demonstrate that Type 2 diabetes studies are more generalizable with regard to age than they are with regard to HbA1c. We found that the generalizability of age increased from Phase 1 to Phase 3 while the generalizability of HbA1c decreased during those same phases. This method can generalize to other medical conditions and other continuous or binary variables. We envision the potential use of EHR data for examining the generalizability of clinical trials and for defining population-representative clinical trial eligibility criteria.
Correspondence to:
Chunhua Weng, PhD
Assistant Professor
Department of Biomedical Informatics
Columbia University
622 W 168 ST, VC-5
New York, NY 10032
Email: cw2384@columbia.edu

Appl Clin Inform 2014; 5: 463–479
DOI: 10.4338/ACI-2013-12-RA-0105
received: December 18, 2013
accepted: April 9, 2014
published: May 7, 2014
http://dx.doi.org/10.4338/ACI-2013-12-RA-0105
Introduction

Clinical trials are the gold standard for generating new high-quality medical evidence. Many clinical trials are designed to emphasize internal validity, and some decisions may compromise external validity. When a clinical trial has limited generalizability, the study results can be difficult to translate to the real-world population that would otherwise be the users of the study information. In fact, this common problem is a concern of both the public and the clinical research community [1, 2], and has significantly impaired the cost-benefit ratio of many clinical trials [3]. Moreover, disease-specific evidence accumulated from multiple clinical trials can greatly influence clinical decisions of care providers [4-7], but little is known about how the populations of multiple trials collectively represent the real-world population with the condition despite the fact that such knowledge is important for patient-centered outcomes research (PCOR) [8].

Each clinical trial has three populations: the real-world patient population, the target population of this study, and the study population or study sample. The real-world patient population represents the set of individuals to whom the results of the trial might be applied. The target population represents a subset of the real-world population who can be enrolled in the study according to ethical or other concerns and must be defined in advance with unambiguous inclusion and exclusion eligibility criteria. In contrast, the study population defines the type of individuals who are enrolled in clinical trials. Information about the study population is often only available after the trial is complete and is summarized in the publications for that trial. Ideally, the study population should represent the target population. However, in reality, the study population often fails to represent the target population for many reasons, such as recruitment problems [9, 10].

Many have reported the compromised generalizability of study population for clinical trials in various disease domains, such as inflammatory bowel disease [11], rheumatoid arthritis [12], heart failure [10], Alzheimer’s disease [13], and dementia [9], but these prior studies on the generalizability of study samples to the patient population largely relied on manual comparisons between the study participants for a few or a dozen of clinical trials and the patient characteristics of convenient patient samples so that they do not scale to include thousands of trials. Moreover, none has addressed corresponding differences between the target populations of clinical trials and the patient population. There is a paucity of scalable methods that systematically and efficiently assess the differences between target populations for clinical trials and the pertinent patient populations for any disease topic of interest.

We face an opportunity to address this need. Lately, the promise of data-driven decision-making has been recognized broadly, especially in the past 2–3 years. Specifically, in biomedicine, the recent burgeoning adoption of the electronic health record (EHR) has made it practical to prescreen potentially eligible patients for clinical trials [14-16] and practical to electronically assess the feasibility of meeting recruitment targets. Notable related efforts include EHR4CR (http://www.ehr4cr.eu) and TRANSFoRm (http://www.transformproject.eu), and i2b2 (https://www.i2b2.org). EHRs are also useful for studying distributions of disease indicators [17, 18], such as hemoglobin A₁c (HbA₁c) and serum glucose, in both inpatient and outpatient populations. Meanwhile, the mandatory public registry for clinical trials, ClinicalTrials.gov [19], provides rich information from more than 160,000 clinical trials investigating thousands of diseases, facilitating systematic analysis of the distributions of the characteristics of clinical trial target populations, as reflected in recruitment eligibility criteria, which can be downloaded, parsed, and aggregated [20-28].

Therefore, we hypothesize that ClinicalTrials.gov and EHRs together offer an opportunity for using electronic data to compare the aggregated target populations in clinical trials with the real-world population captured by EHRs. Such comparisons may inform policy makers or clinical trial sponsors which patient subgroups are understudied and therefore should be considered for future clinical trial interventions, or, conversely, which patient subgroups are overly studied so that the “return of investment” of future studies would be marginal. The comparisons may also identify the gaps between existing medical evidence and the needs of the patient population to guide clinical investigators to design population-representative clinical trial eligibility criteria and select target populations that are both feasible to recruit and also meaningful clinically. A collaboratory called PACeR (Partnership to Advance Clinical Electronic Research) is studying this area [29].
This paper contributes an original method for aggregating clinical trial eligibility criteria across clinical trials of the same medical condition and comparing their distribution with the distribution of the EHR patient population with the same disease. We illustrated this type of data-driven approach for clinical trial generalizability analysis using Type 2 diabetes as an example. We aggregated two representative eligibility variables, age and HbA\(_1c\), from the eligibility criteria of 1,761 Type 2 diabetes trials, and compared them with the corresponding measures for the Type 2 diabetes patients, both inpatients and outpatients, in our EHR at Columbia University Medical Center. This study investigated the feasibility of using electronic data to assess how the aggregated target populations of Type 2 diabetes trials represent a diabetes patient population. On this basis, we discuss the implications of our results and future work.

**Methods**

### 1. Dataset Preparation

Our dataset preparation includes the following steps:

1. Identification of Type 2 diabetes patients using EHR data;
2. Selection of quantifiable measures to characterize and profile Type 2 diabetes patients in trials and in the EHR; and
3. Extraction of quantifiable measures from ClinicalTrials.gov and EHR.

#### Step 1.1 Type 2 Diabetes Patients Identification in EHR

There are multiple methods for phenotyping or cohort identification for Type 2 diabetes using EHRs, including notable efforts ongoing at the eMERGE consortium [30-33]. Given the significant data quality problems in EHR data [34], such as information incompleteness [35], inconsistency, and inaccuracy, both structured and unstructured clinical data, including diagnosis codes, clinical notes, medication orders, and laboratory test results, should be used together to identify Type 2 diabetes patients [32]. However, implementation of such a comprehensive approach entails high costs of developing or adapting natural language processing (NLP) methods for various types of clinical notes of varying local formats due to the frequent lack of portability of NLP algorithms [36], and substantial efforts needed to reconcile inconsistent information from structured and unstructured clinical data [37, 38]. Despite the controversy around the Positive-Predictive-Value (PPV) of using administrative coding for Type 2 diabetes [39, 40] for cohort identification, investigators have found ICD-9 diagnosis codes (‘250.XX’) to be an acceptable cost-effective method to identify Type 2 diabetes patients from EHRs in several previous studies [30, 31, 33] with a PPV up to 91% [40]. Building on the success of these studies, this study used only structured data to identify Type 2 diabetes patients who had the following characteristics:

1. ICD-9 diagnosis codes for Type 2 diabetes on two or more occasions;
2. No ICD-9 diagnosis codes for Type 1 diabetes; and
3. HbA\(_1c\) measurements on one or more occasions regardless of their temporal relationships to diagnosis times.

In addition, we used a list of published Type 2 diabetes medication names [41, 42] to query the medication order records for these patients.

#### Step 1.2 Quantifiable Measure Selection for Characterizing Type 2 Diabetics

We compared the trial target population to the EHR patient population for Type 2 diabetes by HbA\(_1c\) and age distributions. Frequent eligibility criteria for Type 2 diabetes trials include serum creatinine, glucose, HbA\(_1c\), and body mass index. For this feasibility study that intends to generalize to any disease variable in the future, we chose HbA\(_1c\) to characterize Type 2 diabetes patients because it is commonly available in clinical trial eligibility criteria [21] and EHR. The count of HbA\(_1c\) measures in a diabetes patient’s EHR ranges from 1 to 172 (Supplement Figure 1). We chose age as a demographic criterion to complement the HbA\(_1c\) evaluation.
Step 1.3 Data Extraction from ClinicalTrials.gov and EHR

Two datasets were needed for the proposed analysis. The trial summary dataset included the eligibility criteria for age and HbA₁c for Type 2 diabetes trials from ClinicalTrials.gov for profiling the aggregated target populations. The real-world population summary dataset included our EHR data for date of birth and all HbA₁c values with timestamps for the Type 2 diabetes patients sampled using the aforementioned method.

To develop the trial summary dataset, in March 2012, we searched ClinicalTrials.gov using the keyword “diabetes” in the “condition” field of the online trial search form and identified 5,652 Type 2 diabetes mellitus trials (T1). Among these trials, we identified a subset of 4,765 trials with a known status (i.e., closed or open) and valid age criteria with specific value ranges (T2). Within T2, we identified 1,761 trials with known status and HbA₁c criteria with specific value ranges (T3). We included T2 for analyzing age distribution and T3 for analyzing HbA₁c distribution. We downloaded the following structured information for each of the 1,761 trials: ClinicalTrials.gov registry number (NCT ID), title, recruitment status, conditions, interventions, sponsors, gender, age groups, phases, start date, sponsor, inclusion criteria, and exclusion criteria.

Clinical trials for Type 2 diabetes focus on patients from different age groups or with varying HbA₁c values. For example, trial NCT00174681 requires HbA₁c between 6% and 8%, whereas trial NCT01341067 requires HbA₁c between 7% and 17%. One author (Zhang) extracted the value ranges for age from our trial set T2 (N = 4,765) and the value ranges for HbA₁c from our trial set T3 (N = 1,761) respectively through manual review of their free-text eligibility criteria. In addition, in most of trials, eligibility criteria are expressed as separate inclusion criteria and exclusion criteria. We transformed all exclusion criteria for age and HbA₁c into inclusion criteria. For example, if a trial excluded “patients with age >75 years old”, we manually replaced this exclusion criterion with its equivalent inclusion criterion “patients with age ≤75 years old”.

To develop the real-world population summary, we used the Columbia University Medical Center’s clinical data warehouse [43], which contains over 20 years of health information for about 4.5 million patients with diverse ethnicities. We used all 20 ICD-9 codes for Type 2 diabetes — 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92 to identify 116,308 patients who had at least one of these codes at least once (P1). Among P1, 63,568 patients received at least one code on at least two clinical encounters (P2), in which 45,285 had no diagnosis code for Type 1 diabetes (P3). Among P3, 26,120 patients had both date of birth and HbA₁c values and formed the patient population for this study (P4). This patient population (P4) was 51% female, 63 years old on average, 45.9% White, 35.7% Hispanic or Other, 16% Black, and 1.7% Asian. We divided P4 into two groups: patients with orders for at least one of the Type 2 diabetes medications (P5, N = 19,096) and patients without orders for Type 2 diabetes medications (P6, N = 7,024).

2. Data Analysis

Our analysis also consisted of three steps. We first aggregated eligibility criteria from all the sample Type 2 diabetes trials and drew the histograms of the percentages of trials over the values for age or HbA₁c. We further stratified the trials by phase, gender, and race, and drew the histograms of trials for HbA₁c and age for each phase. Then we drew the histograms of the percentages of Columbia University Medical Center’s Type 2 diabetes patients over the range of values for age and HbA₁c. Because some patients in our sample had more than one HbA₁c value, we generated separate histograms for the earliest, latest, median, mean, and middle-measurement-time HbA₁c values. On this basis, we juxtaposed the histograms for trials and patients in the same figure to contrast the distributions of trials and patients over HbA₁c values and age values.

Step 2.1 Generating the histograms for Type 2 Diabetes Trials over the HbA₁c and age value ranges respectively

Since we used the same method to derive a distribution function for both age and HbA₁c, next we describe this process for calculating the trial distribution within variable value ranges using HbA₁c as an example. This process can be illustrated with a simple scenario using the aforementioned trials
NCT00174681 and NCT01341067. In this scenario, trial NCT00174681 covers value range [6%, 8%], and trial NCT01341067 covers value range [7%, 17%]. According to the method introduced below, five connected bins would be created: (−∞, 6%), [6%, 7%], (7%, 8%), (8%, 17%), and (17%, ∞+), which together cover the entire value range (−∞, ∞+). Stepwise bin divisions and results are shown in Table 1.

We hypothesized that eligible target populations are evenly distributed within each bin so that each value within the range of a bin is assigned the same number of trials. For example, if there are N trials that recruit patients with HbA\textsubscript{ic} between 8% and 17%, there are N trial opportunities for each discrete value within this range (e.g., 9%, 10%, etc). On this basis, we drew the histograms for trials, whose X-axis represent HbA\textsubscript{ic} or age value and whose Y-axis represents the percentage of trials among the trials of each phase or among all the trials recruiting patients with that value.

Next we describe the algorithm for the above procedure. Below, [ ] means being inclusive, while () means being non-inclusive; ∞ refers to negative infinity, whereas ∞+ refers to positive infinity. Each trial \( T_i \) \( (i = 1, 2, \dotsc, 1,761) \) has a value range \([\text{HbA}_{1c_{\text{min}}}, \text{HbA}_{1c_{\text{max}}}]\). We used the minimum lower bound, designated as \( \text{HbA}_{1c_{\text{min}}} \), and the maximum upper bound designated as \( \text{HbA}_{1c_{\text{max}}} \) to create two additional value ranges, negative infinity \((\langle \text{HbA}_{1c_{\text{min}}} \rangle)\) and positive infinity \((\text{HbA}_{1c_{\text{max}}} , \infty+)\). These two value ranges along with the existing value range \([\text{HbA}_{1c_{\text{min}}} \langle \text{HbA}_{1c_{\text{max}}} \rangle] \) together form the entire range \((−∞, +∞)\) of all possible HbA\textsubscript{ic} values. Then, we sorted all the upper and lower bounds in the ascending order and used them to divide the entire value range into connected but non-overlapping smaller bins of varying width. For each bin, we calculated the number of trials that include the corresponding HbA\textsubscript{ic} value range in their HbA\textsubscript{ic} eligibility criterion. One trial may cover multiple bins. Then, we drew a curve whose X-axis is HbA\textsubscript{ic} value and whose Y-axis is the number of trials divided by the total, 1,761, representing the percentage of trials falling into this bin.

Later, we used Local Polynomial Regression Fitting to smoothen the distribution curve. This function further divided the bins of varying width to smaller bins of equal width. For example, the bin (8%, 17%) was expanded to 10 smaller bins, including (8%, 9%), (9%, 10%), (10%, 11%), (11%, 12%), (12%, 13%), (13%, 14%), (14%, 15%), (15%, 16%), (16%, 17%), (17%, 18%). All these bins have the equal likelihood to enroll patients. According to Table 1, if one trial falls into the bin of (8%, 17%), then each of the small bin has one trial. The interpretation is “if there exists one trial enrolling patients whose A\textsubscript{ic} is >8 and ≤17, then there is one trial enrolling patients whose A\textsubscript{ic} is >8 and ≤9, one trial enrolling patients whose A\textsubscript{ic} ≥9 and <10, and so on.”

### Step 2.2 Creating histograms of patients over age and HbA\textsubscript{ic} respectively

For each Type 2 diabetes patient in the EHR, we obtained all the HbA\textsubscript{ic} values and date of birth; the latter was used to calculate the patient’s age at the earliest, middle, and latest HbA\textsubscript{ic} measurement times. For example, if a patient had 5 HbA\textsubscript{ic} measurements at ages of 10, 11, 15, 17, 20 respectively, the earliest, middle, and latest measurement times were 10, 15, and 20 respectively. Then, we drew histograms for age and HbA\textsubscript{ic} respectively for the patient population, where the X-axis represents the earliest, latest, mean, median, and middle-measurement-time value of HbA\textsubscript{ic}, or age at the earliest, latest, and median measurements, and the Y-axis is the percentage of patients with that value.

### Step 2.3 Juxtaposition of the distributions of trials and patients

In the trials histogram, the Y-axis represents the percentage of trials that include the value on X-axis in the inclusion criteria, whereas in the patient population histogram, the Y-axis represents the percentage of patients with the value on X-axis. We juxtaposed the trial and patient distributions for both variables and for both patient groups.

We developed the Generalizability Index for Study Traits (GIST) as a metric to evaluate the relative generalizability of a study characteristic from a set of clinical trials to a real-world population. GIST is the sum across all intervals of the proportion of trials including patients in that interval, multiplied by the proportion of patients in the real-world population observed in that interval.

\[
\text{GIST} = \sum_{j=1}^{N} \frac{\sum_{i=1}^{W} (I(\text{low}_j <= y_i <= \text{high}_j))}{P} \times \frac{1}{T} \times \sum_{k=1}^{P} (I(\text{low}_k <= y_k <= \text{high}_k))
\]
Where \( N \) is the number of distinct intervals of the study trait, \( T \) is the number of trials, \( P \) is the number of patients in the population, \( w_i \) is the inclusion interval for the \( j \)th study, such that an indicator \( I \) can be defined when the \( j \)th study interval subsumes the \( i \)th interval low and high boundary threshold, and \( y_k \) is the observed value of the characteristic for the \( k \)th patient such that an indicator \( I \) can be defined when the \( k \)th patient's value falls within the \( i \)th interval.

The GIST metric is on a 0 to 1 scale that characterizes the proportion of real-world population that would be eligible across the clinical trial studies, with 1 being perfectly generalizable (all patients would be eligible for all studies), and 0 being completely not generalizable (no real-world patients would be eligible for any studies).

As a motivating example, assume we wanted to estimate the generalizability of two studies for a treatment of a disease, that both were restricted to patients aged 20–50. If in the real-world population of 100 patients, we found all patients with that disease fell between the ages of 20–50, we would say the study was perfectly generalizable on the study trial of age; GIST = 1 because there is only one interval (20–50), 100% of trials cover this interval and 100% of patients fall within this interval. In contrast, if all the real-world patients were found to be >50, we would say the study results could not be generalized to the real-world population on the basis of age; GIST = 0 because there are two intervals (20–50, 51-inf), 100% of trials cover the 20–50 interval, but 0% of trials cover the 51-inf interval, whereas 0% of patients fall within the 20–50 interval, and 100% of patients fall in the 51-inf interval. Now assume one study imposed a restriction on age of 20–50, but the other study only imposed a restriction of age ≥20, and assume 10 patients were <20, 60 patients were 20–50, and 30 patients were >50; in this case, there were three observed intervals: 0–20, 20–50; 50-inf. The trial coverage would be 0%, 100%, 50% across these three intervals. The real-world population proportions would be 10%, 60%, 30% across the same intervals. Accordingly, \( \text{GIST} = 0\% \times 10\% + 100\% \times 60\% + 30\% \times 50\% = 0.75. \)

The GIST metric can be used to evaluate the generalizability of one study or a collection of studies and can be applied to any study characteristic that is observed in the real-world population, including binary, categorical, and continuous-valued attributes. We applied GIST to two study traits: HbA\(_{1c}\) and age, for the collection of all Type 2 diabetes studies, as well as the subset of studies classified as Phase I, Phase II, Phase III, and Phase IV.

**Results**

Of the 1,761 trials, 21.2% did not have phase information, 0.3% were phase 0, 10.7% were phase I, 21.6% were phase II, 27.9% were phase III, and 18.2% were phase IV; 95.6% (\( N = 1,683 \)) were interventional and the rest (\( N = 81 \)) observational; 96.6% recruited patients of both genders, 2% recruited only male patients, and 1.3% recruited only female patients. Only 10 trials had restrictions for race or ethnicity; all others recruited patients regardless of their race and ethnicity. Therefore, study type, gender, and race (or ethnicity) are not likely to affect the results; accordingly, we stratified the 1,761 trials only by significant phases (i.e., phase I, II, III, and IV).

We generated two figures to illustrate how the patient population compares with trial populations: one for HbA\(_{1c}\) (Figure 1) and the other for the age (Figure 2). They show the peak values and percentages of trials at the peak values for the distributions of Type 2 diabetes trials of four phases over the value ranges for HbA\(_{1c}\) and age respectively.

Independent from diabetes medication status, a person 44 years old has the best chance to be included in most (90.8%) Type 2 diabetes trials. A person with HbA\(_{1c}\) value of 8.2 has the best chance to be eligible for most (88.3%) Type 2 diabetes trials. The greatest percentage of Phase I trials (81.9%) recruit patients with an HbA\(_{1c}\) of 8.0, the greatest percentage of Phase II trials (82.5%) recruit most frequently with an HbA\(_{1c}\) value of 7.8, and the greatest percentage of Phase III trials (87.6%) and Phase IV trials (78.6%) recruit most frequently with an HbA\(_{1c}\) value of 8.1. Figure 1 shows that between 40% and 50% of Phase I or II trials recruit patients whose HbA\(_{1c}\) is less than or equal to 6.4, while between 25% or 30% Phases III and IV trials recruit patients of the same HbA\(_{1c}\) value range, indicating that a larger portion of Phases I and II trials define their target population younger and healthier than Phases III and IV trials do.
In Figure 2 the age distribution of Phase I trials is narrower and to the left of that of Phase II, III, and IV trials, which almost align, demonstrating that most (95.9%) Phase I trials recruit significantly younger patients (with peak value around age 39) than most (96%) Phases II, III, and IV trials (with peak value of 50 or 55). Figure 2 shows that about 20% of Phases I or II trials recruit patients younger than 20 years old, while only about 10% Phases III or IV trials recruit patients of the same age range. From age 50 to 63, the percentage of Phase I trials recruiting patients of this age range drops markedly from 90% to 65%, while the percentages of Phases II, III, and IV trials recruiting the same patient group remain stable at around 96%. These results indicate that Phases I and II trials recruit younger and healthier patients than Phases III and IV trials. The age distributions for trials of different phases are all wider than the age distributions of the patients and are consistently to the left of the age distributions of patients, showing that trials attempt to recruit participants younger than Type 2 diabetes patients, especially in Phases I and II trials.

Regardless of trial stratification by phase, patient stratification by HbA1c measurement time or type, and patient stratification by medication order status, the distributions of trials are always to the right of the distributions of patients, implying that trials attempt to recruit patients with higher HbA1c values than are found among Type 2 diabetes patients. In contrast, the distributions of trials are always to the left of the distributions of patients, implying that trials attempt to recruit patients younger than are found among Type 2 diabetes patients. Figure 1 and Figure 2 together show that Type 2 diabetes trials tend to recruit young and sick (i.e., with high HbA1c values) diabetes patients.

Table 2 shows the GIST for HbA1c and age across all trials and within the individual phases. The Type 2 diabetes clinical trials had a GIST of 0.51 for HbA1c overall, with the index decreasing from 0.59 to 0.50 from Phase I to Phase III studies. The study were observed to have greater generalizability for age (i.e., an overall GIST of 0.75), with GIST = 0.67 for Phase I increasing to GIST = 0.86 for Phase III studies.

Discussion

Implications

This study contributes an early data-driven approach for illustrating the differences between aggregated target populations for Type 2 diabetes trials, represented by selected eligibility criteria variables for Type 2 diabetes trials, and diabetes patient populations that are available for study, represented by their corresponding EHR data. It also shows the feasibility of using electronic data, such as ClinicalTrials.gov and EHRs, for comparing clinical trial target populations and clinical patients.

Empirically, HbA1c is directly proportional to age [44, 45]; therefore, it should be easier to recruit older patients with high HbA1c values or younger patients with low HbA1c values. However, Figure 1, Figure 2 and Table 2 together demonstrate that most diabetes trials target younger and sicker diabetes patients (those with high HbA1c values). Although our study does not address the clinical optimality of inclusion criteria of diabetes trials, it reveals the misalignment between aggregated clinical trial target populations and patient populations, suggesting that in certain patient subgroups, the amount of research investment is not commensurate with the size of patient populations by recruiting overrepresented or underrepresented patients from clinical settings.

We developed GIST as a single metric to provide a relative assessment of generalizability of a given study attribute. We found diabetes studies are more generalizable with respect to age than with regards to HbA1c. This is consistent with clinical expectations, since there is general consensus that Type 2 diabetes can inflict patients 18 years and over and all ages may be eligible for treatment, whereas there is greater debate about the proper thresholds for HbA1c that should be used for diagnosis and a targeted maintenance range. Also, clinical trials may opt to be more restrictive with HbA1c than age, because study sponsors may think that patients with lower HbA1c values do not have sufficient blood glucose imbalance or that patients with high values may be too far out-of-control to be considered the primary targeted candidates for a given intervention. The differences in GIST across phases were also informative. The GIST values for age increased from Phase I to Phase III, potentially because study sponsors may be more conservative with inclusion of older patients.
during early studies aimed at establishing safety and initial efficacy, whereas broaden their scope during Phase III when the targeted indication is under investigation. In contrast, we observed the GIST values for HbA$_{1c}$ decreased from Phase I to Phase III, perhaps because study designers sought tighter control of the HbA$_{1c}$ range to test efficacy in the larger studies.

There can be many reasons behind the differences, including a possible good clinical rationale. As Altman pointed out, in general, but not always, we do not expect treatment to do much for patients who already have an excellent prognosis, nor for those with a dire prognosis [46]. Still, it is important to show such differences and provide a means for trial designers to gain a transparent overview of research distributions and for predicting trial representativeness of the general patient population. Understanding what clinical rationale justifies the differences could be a separate study, yet we see the opportunity of using EHR data to inform rational clinical trial eligibility criteria designs in the future.

**Limitations**

The major limitations of this study are its use of a small number of structured data elements from EHR, ClinicalTrials.gov data quality problems, and EHR data complexity and quality problems.

**Methodology Limitations**

Various algorithms have been proposed for identifying diabetic patients from EHRs, some of which use clinical notes and medication information. Our reliance on ICD-9 diagnosis codes may have missed the undiagnosed diabetes population or included misdiagnosed non-diabetic patients. Moreover, we included only EHR data for two variables, age and HbA$_{1c}$, to profile diabetes patients from one hospital. Other variables, such as glucose, body mass index, comorbidities, and medications, are either more complex with contextual measurements or exist as free text and, as such, are difficult to parse and quantify. It would be helpful to use more disease biomarkers to generate temporal profiles for patients, but we believe that modeling the relationships of variables disease biomarkers is an independent research topic that warrants further studies that are beyond the scope of this feasibility study.

To ensure a highly accurate dataset, for this study, we manually extracted age and HbA$_{1c}$ from ClinicalTrials.gov. Use of natural language processing would improve the efficiency of this task [20, 22]. The manually created dataset serves as an important gold standard for us to develop a separate automated algorithm for extracting numerical expressions from ClinicalTrials.gov. The design and evaluation of that algorithm for assisting with automated aggregation of clinical trial target populations are beyond the scope of this paper but we are preparing a manuscript about a generalizable rule-based algorithm for extracting numerical expressions from eligibility criteria text so that others who want to replicate this study’s results or apply the method on other diseases or other numerical variables do not have to perform manual processes for data extraction and review. This algorithm is available online: http://columbiaelixr.appspot.com/valx. Its preliminary precision and recall for HbA$_{1c}$ using the gold standard created from this study are 98.9% and 97.1%, respectively.

Formal comparison over categorical or binary variables needs to overcome challenges for aggregating heterogeneous semantic concept representations in EHRs. Our simplified aggregate analysis with one binary variable showed that about 38% Type 2 diabetes trials exclude patients with renal failures or kidney diseases, while 3% include patients with related kidney conditions. In contrast, these kidney conditions are prevalent in about 22% of the Type 2 diabetic population in our EHR.

**Data Quality issues in ClinicalTrials.gov**

While ClinicalTrials.gov is a tremendous resource and utility for the community, the nature of reporting and free text form that much of the information it provides presents several data quality challenges to research. It is likely that the “Conditions” field’s information was not 100% accurate so that we may have missed some Type 2 diabetes trials. In addition, the eligibility criteria summaries may be incomplete [47]. Consequently, we may have mistakenly excluded some diabetes studies that did not have HbA$_{1c}$ values on ClinicalTrials.gov but had that information in the corresponding
protocols, which may affect our trial distribution analysis. We also noticed some inconsistency in the eligibility criteria on ClinicalTrials.gov. For example, one source in a study may indicate “inclusion criteria: gender: both” and another “exclusion criterion: male”. We also did not consider the heterogeneity of clinical trial interventions and outcomes when we aggregated these trials’ target populations. We did not stratify trials by their purposes and intervention types, partially because such information may be incomplete and inaccurate. For example, we only retrieved 187 trials using the search “comparative effectiveness” as of July 2013. Again, such granular analysis requires sophisticated and specialized NLP support that we do not have now.

**Data Quality issues in EHR**

Data quality issues in EHR provide an additional limitation of this study. A large fraction of patients did not have HbA$_{1c}$ values even though they had ICD-9 diagnosis codes for Type 2 diabetes. This can happen with patients who visited Columbia University Medical Center occasionally to treat diseases more severe than Type 2 diabetes, such as cancer or heart attack, and whose primary care providers were not at Columbia University Medical Center so that their HbA$_{1c}$ were not regularly collected. Also, as shown in ▶ Supplement Figure 1 ("histogram of HbA$_{1c}$ measures for the Type 2 diabetes patients"), among patients who had HbA$_{1c}$ values, most did not have regular measurements documented in their EHRs even though HbA$_{1c}$ is a standard measure of Type 2 diabetes. This result is consistent with our recently published paper on EHR data completeness for secondary use [35], where we reported that of the patients with data in the clinical data warehouse, 29.3% had at least one visit with a recorded laboratory result (20.0% glucose, 23.0% hemoglobin), 12.6% had at least one with a medication order, and 44.5% had at least one with a diagnosis. Either improving clinical documentation with these targeted areas or using predictive methods to impute values for these variables may overcome these problems.

**Conclusion**

We contribute an original data-driven, distribution-based method for comparing aggregated clinical trial target populations with their intended patient populations. A key merit of this scalable approach is its use of electronic data resources to analyze a large number of clinical trials and patients simultaneously, a scale not possible using existing non-electronic methods, to show the transparency of the generalizability of clinical trials. Making clinical trial populations generalizable to real-world patients is important. This method can potentially bring us one step closer to this goal. Future studies are needed to evaluate the GIST measure.

**Funding**

This study was sponsored by National Library of Medicine grants R01LM009886, R01LM010815, and R01LM006910, and by National Center for Advancing Translational Sciences grant UL1TR000040.

**Contributorship**

CW initiated the concept, supervised data collection and analysis, and wrote the manuscript. YL and PR analyzed data and helped write the data analysis methodology. YZ and FL collected data for clinical trials. JG contributed ideas for data analysis. PR invented GIST. PR, GH and JTB advised CW and made substantial methodology contributions.

**Clinical Relevance Statement**

This study contributes an informatics approach to assess the generalizability of clinical trials and to increase the transparency of clinical trial generalizability for the public and healthcare providers. It has significance for evidence-based medicine and learning health systems.

**Conflicts of Interest**

None
Protection of Human and Animal Subjects
The study was performed in compliance with the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, and was approved by the Columbia University Medical Center Institutional Review Board.
Fig. 1 For each HbA₁c value on X, the red lines indicate the percentage of trials of different phases whose eligibility criteria include that value and the blue lines indicate the percentage of patients whose earliest, latest, mean, median, or middle collection-time HbA₁c was that value.
Fig. 2 For each age value on X, the red solid line indicates the percentage of trials of different phases whose eligibility criteria include that value and the blue lines indicate the percentage of patients who were that age at the earliest, median, or latest HbA1c measurements.
Table 1  Stepwise bin divisions and calculation of trial counts in each bin. NCT00174681: Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes. NCT01341067: Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes (DexlonT2)

<table>
<thead>
<tr>
<th>Bin</th>
<th>Included trial(s)</th>
<th>Number of trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-∞, 6%)</td>
<td>N/A</td>
<td>0</td>
</tr>
<tr>
<td>[6%, 7%)</td>
<td>NCT00174681</td>
<td>1</td>
</tr>
<tr>
<td>(7%, 8%)</td>
<td>NCT00174681, NCT01341067</td>
<td>2</td>
</tr>
<tr>
<td>(8%, 17%]</td>
<td>NCT01341067</td>
<td>1</td>
</tr>
<tr>
<td>(17%, ∞+)</td>
<td>N/A</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2  GIST for Type 2 Diabetes Trials for HbA1c and Age in Different Phases

<table>
<thead>
<tr>
<th>Clinical Trials</th>
<th>HbA1c</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>All (N = 1761)</td>
<td>0.51</td>
<td>0.75</td>
</tr>
<tr>
<td>I (N = 188)</td>
<td>0.59</td>
<td>0.67</td>
</tr>
<tr>
<td>II (N = 380)</td>
<td>0.55</td>
<td>0.82</td>
</tr>
<tr>
<td>III (N = 491)</td>
<td>0.50</td>
<td>0.86</td>
</tr>
<tr>
<td>IV (N = 321)</td>
<td>0.50</td>
<td>0.82</td>
</tr>
</tbody>
</table>
References


